Compounds 4a-j Research Articles

Synthesis, Characterization and Antifungal Studies of Novel Substituted Benzaldehyde Derivatives of 2-Amino-6-ferrocenyl-4-phenylpyrimidine

A series of novel 2-amino-6-ferrocenyl-4-phenylpyrimidine (AFPP) derivatives (6a-j) have been synthesized by coupling AFPP with thioglycolic acid and various substituted benzaldehydes (a-j) using standard 1,3-dicyclohexylcarbodiimide (DCC) protocol. The synthesized compounds were characterized by FTIR, 13C NMR, 1H NMR and MS techniques. The synthesized compounds 6a-j were evaluated for antifungal activities against Candida albicans MTCC 183. Comparing compounds 6a-j to standard amphotericin B, it was found that the synthesized compounds showed excellent activity.

Synthesis, In Silico Study, and In Vitro Antifungal Activity of New 5-(1,3-Diphenyl-1H-Pyrazol-4-yl)-4-Tosyl-4,5-Dihydrooxazoles.

The increase in multi-drug resistant Candida strains has caused a sharp rise in life-threatening fungal infections in immunosuppressed patients, including those with SARS-CoV-2. Novel antifungal drugs are needed to combat multi-drug-resistant yeasts. This study aimed to synthesize a new series of 2-oxazolines and evaluate the ligands in vitro for the inhibition of six Candida species and in silico for affinity to the CYP51 enzymes (obtained with molecular modeling and protein homology) of the same species. The 5-(1,3-diphenyl-1H-pyrazol-4-yl)-4-tosyl-4,5-dihydrooxazoles 6a-j were synthesized using the Van Leusen reaction between 1,3-diphenyl-4-formylpyrazoles 4a-j and TosMIC 5 in the presence of K2CO3 or KOH without heating, resulting in short reaction times, high compound purity, and high yields. The docking studies revealed good affinity for the active site of the CYP51 enzymes of the Candida species in the following order: 6a-j > 4a-j > fluconazole (the reference drug). The in vitro testing of the compounds against the Candida species showed lower MIC values for 6a-j than 4a-j, and for 4a-j than fluconazole, thus correlating well with the in silico findings. According to growth rescue assays, 6a-j and 4a-j (like fluconazole) inhibit ergosterol synthesis. The in silico toxicity assessment evidenced the safety of compounds 6a-j, which merit further research as possible antifungal drugs.

Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies.

A new class of benzimidazole-based derivatives (4a-j, 5, and 6) with potential dual inhibition of EGFR and BRAFV600E has been developed. The newly synthesized compounds were submitted for testing for antiproliferative activity against the NCI-60 cell line. All newly synthesized compounds 4a-j, 5, and 6 were selected for testing against a panel of sixty cancer cell lines at a single concentration of 10 µM. Some compounds tested demonstrated remarkable antiproliferative activity against the cell lines tested. Compounds 4c, 4e, and 4g were chosen for five-dose testing against 60 human tumor cell lines. Compound 4c demonstrated strong selectivity against the leukemia subpanel, with a selectivity ratio of 5.96 at the GI50 level. The most effective in vitro anti-cancer assay derivatives (4c, 4d, 4e, 4g, and 4h) were tested for EGFR and BRAFV600E inhibition as potential targets for antiproliferative action. The results revealed that compounds 4c and 4e have significant antiproliferative activity as dual EGFR/BRAFV600E inhibitors. Compounds 4c and 4e induced apoptosis by increasing caspase-3, caspase-8, and Bax levels while decreasing the anti-apoptotic Bcl2 protein. Moreover, molecular docking studies confirmed the potential of compounds 4c and 4e to act as dual EGFR/BRAFV600E inhibitors.

Synthesis of a new series of 4-pyrazolylquinolinones with apoptotic antiproliferative effects as dual EGFR/BRAFV600E inhibitors.

The current study focuses on developing a single molecule that acts as an antiproliferative agent with dual or multi-targeted action, reducing drug resistance and adverse effects. A new series of 4-pyrazolylquinolin-2-ones (5a-j) with apoptotic antiproliferative effects as dual EGFR/BRAFV600E inhibitors were designed and synthesized. Compounds 5a-j were investigated for their cell viability effect against a normal cell line (MCF-10A). Results showed that none of the compounds were cytotoxic, and all 5a-j demonstrated more than 90% cell viability at 50 μM concentration. Using erlotinib as a reference, the MTT assay investigated the antiproliferative impact of targets 5a-j against four human cancer cell lines. Compounds 5e, 5f, 5h, 5i, and 5j were the most potent antiproliferative agents with GI50 values of 42, 26, 29, 34, and 37 nM, making compounds 5f and 5h more potent than erlotinib (GI50 = 33 nM). Moreover, compounds 5e, 5f, 5h, 5i, and 5j were further investigated as dual EGFR/BRAFV600E inhibitors, and results revealed that compounds 5f, 5h, and 5i are potent antiproliferative agents that act as dual EGFR/BRAFV600E inhibitors. Cell cycle analysis and apoptosis detection revealed that compound 5h displaying cell cycle arrest at the G1 transition could induce apoptosis with a high necrosis percentage. Docking studies revealed that compound 5f exhibited a strong affinity for EGFR and BRAFV600E, with high docking scores of -8.55 kcal mol-1 and -8.22 kcal mol-1, respectively. Furthermore, the ADME analysis of compounds 5a-j highlighted the diversity in their pharmacokinetic properties, emphasizing the importance of experimental validation.

Synthesis, Anticancer Activity, and In Silico Studies of 5-(3-Bromophenyl)-N-aryl-4H-1,2,4-triazol-3-amine Analogs.

In the current study, we described the synthesis of ten new 5-(3-Bromophenyl)-N-aryl-4H-1,2,4-triazol-3-amine analogs (4a-j), as well as their characterization, anticancer activity, molecular docking studies, ADME, and toxicity prediction. The title compounds (4a-j) were prepared in three steps, starting from substituted anilines in a satisfactory yield, followed by their characterization via spectroscopic techniques. The National Cancer Institute (NCI US) protocol was followed to test the compounds' (4a-j) anticancer activity against nine panels of 58 cancer cell lines at a concentration of 10-5 M, and growth percent (GP) as well as percent growth inhibition (PGI) were calculated. Some of the compounds demonstrated significant anticancer activity against a few cancer cell lines. The CNS cancer cell line SNB-75, which showed a PGI of 41.25 percent, was discovered to be the most sensitive cancer cell line to the tested compound 4e. The mean GP of compound 4i was found to be the most promising among the series of compounds. The five cancer cell lines that were found to be the most susceptible to compound 4i were SNB-75, UO-31, CCRF-CEM, EKVX, and OVCAR-5; these five cell lines showed PGIs of 38.94, 30.14, 26.92, 26.61, and 23.12 percent, respectively, at 10-5 M. The inhibition of tubulin is one of the primary molecular targets of many anticancer agents; hence, the compounds (4a-j) were further subjected to molecular docking studies looking at the tubulin-combretastatin A-4 binding site (PDB ID: 5LYJ) of tubulin. The binding affinities were found to be efficient, ranging from -6.502 to -8.341 kcal/mol, with two major electrostatic interactions observed: H-bond and halogen bond. Ligand 4i had a binding affinity of -8.149 kcal/mol with the tubulin-combretastatin A-4 binding site and displayed a H-bond interaction with the residue Asn258. The ADME and toxicity prediction studies for each compound were carried out using SwissADME and ProTox-II software. None of the compounds' ADME predictions showed that they violated Lipinski's rule of five. All of the compounds were also predicted to have LD50 values between 440 and 500 mg/kg, putting them all in class IV toxicity, according to the toxicity prediction. The current discovery could potentially open up the opportunity for further developments in cancer.

Synthesis, Characterization and Biological Evaluation of Some Novel Pyrrolopyrimidine Analogues

The evidences over drug resistance, narrow spectrum and side effects of commercially available antimicrobials intended present study to carry out synthesis and antimicrobial evaluation of some novel pyrrolopyrimidine analogues. Current study involved synthesis of some novel 4-[2-(substituted benzylidene)hydrazinyl]-7H-pyrrolo[2,3-d]pyrimidines (2a-j) followed by evaluation of their antimicrobial potential against bacterial and fungal strains. The synthesis of new pyrrolopyrimidine analogues 2a-j, was carried out in two distinct stages. In first step, azo compound 4-hydrazinyl-7H-pyrrolo[2,3-d]pyrimidine was synthesized by reacting hydrazine hydrate with 4-chloropyrrolopyrimidine, whereas in second step, novel imino analogues of 4-hydrazinyl-7H-pyrrolo[2,3-d]pyrimidines (2a-j) were synthesized by treating with various substituted benzaldehydes. All the synthesized compounds were subjected to characterization based on IR, 1H NMR and CHN analysis data. The synthesized compounds were also evaluated for their antibacterial and antifungal potential using disc diffusion method. Results of present study revealed that tested compounds possess significant inhibitory potential against tested bacterial and fungal strains. Present study concludes that novel compounds 2a-j possess high antibacterial and antifungal potential, however they must be further evaluated preclinically and clinically for their therapeutic significance.

Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents.

Aiming to simultaneously modulate the endocannabinoid system (ECS) functions and the epigenetic machinery, we selected the fatty acid amide hydrolase (FAAH) and histone deacetylase (HDAC) enzymes as desired targets to develop potential neuroprotective multitarget-directed ligands (MTDLs), expecting to achieve an additive or synergistic therapeutic effect in oxidative stress-related conditions. We herein report the design, synthesis, and biological evaluation of the first-in-class FAAH-HDAC multitarget inhibitors. A pharmacophore merging strategy was applied, yielding 1-phenylpyrrole-based compounds 4a-j. The best-performing compounds (4c, 4f, and 4h) were tested for their neuroprotective properties in oxidative stress models, employing 1321N1 human astrocytoma cells and SHSY5 human neuronal cells. In our preliminary studies, compound 4h stood out, showing a balanced nanomolar inhibitory activity against the selected targets and outperforming the standard antioxidant N-acetylcysteine in vitro. Together with 4f, 4h was also able to protect 1321N1 cells from tert-butyl hydroperoxide or glutamate insult. Our study may provide the basis for the development of novel MTDLs targeting the ECS and epigenetic enzymes.

Design, synthesis, anticancer activity and docking studies of novel quinazoline-based thiazole derivatives as EGFR kinase inhibitors

The in vitro anticancer efficacy of a new series of quinazoline-based thiazole derivatives was explored. Three cancer cell lines, MCF-7, HepG2, and A548, as well as the normal Vero cell lines, were tested employing the synthesized quinazoline-based thiazole compounds (4a-j). All of these compounds showed a moderate to significant cytotoxic impact that would have been noticeable and, in some cases, much more pronounced than the widely used drug erlotinib. For the MCF-7, HepG2, and A549 cell lines, respectively, the IC50 values of compound 4i were 2.86, 5.91, and 14.79 μM while those of compound 4j were 3.09, 6.87, and 17.92 μM. For their in vitro inhibitory effects against different EGFR kinases, such as the wild-type, L858R/T790 M, and L858R/T790 M/C797S, all the synthesized compounds were tested. The IC50 values for compound 4f against the wild-type, L858R/T790 M, and L858R/T790 M/C797S mutant EGFR kinases were 2.17, 2.81, and 3.62 nM, respectively. Investigations on the molecular docking of significant molecules indicated potential mechanisms of binding into the EGFR kinase active sites. By using in-silico simulations, compounds' putative drug-like qualities were verified. Finally, it has been shown that the newly synthesized compounds 4i and 4j are good candidates and beneficial for future design, optimization, and research to build more potent and selective EGFR kinase inhibitors with higher anticancer activity.

Synthesis, Antioxidant and Antiproliferative Actions of 4-(1,2,3-Triazol-1-yl)quinolin-2(1H)-ones as Multi-Target Inhibitors.

The reaction of 4-azido-quinolin-2(1H)-ones 1a-e with the active methylene compounds pentane-2,4-dione (2a), 1,3-diphenylpropane-1,3-dione (2b), and K2CO3 was investigated in this study. This approach afforded 4-(1,2,3-triazol-1-yl)quinolin-2(1H)-ones 3a-j in high yields and purity. All newly synthesized products' structures were identified. Compounds 3a-j were tested for antiproliferative activity against a panel of four cancer cell lines. In comparison to the reference erlotinib (GI50 = 33), compounds 3f-j were the most potent derivatives, with GI50 values ranging from 22 nM to 31 nM. The most effective antiproliferative derivatives, 3f-j, were subsequently investigated as possible multi-target inhibitors of EGFR, BRAFV600E, and EGFRT790M. Compound 3h was the most potent inhibitor of the studied molecular targets, with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively. The apoptotic assay results demonstrated that compounds 3g and 3h function as caspase-3, 8, and Bax activators as well as down-regulators of the antiapoptotic Bcl2, and hence can be classified as apoptotic inducers. Finally, compounds 3g and 3h displayed promising antioxidant activity at 10 µM, with DPPH radical scavenging of 70.6% and 73.5%, respectively, compared to Trolox (77.6%).

Chrysin based pyrimidine-piperazine hybrids: design, synthesis, in vitro antimicrobial and in silico E. coli topoisomerase II DNA gyrase efficacy.

Ten chrysin-based pyrimidine-piperazine hybrids have been evaluated in vitro for antimicrobial activity against eleven bacterial and two fungal strains. All compounds 5a-j exhibited moderate to good inhibition, with MIC values ranging from 6.25 to 250µg/ml. At 6.25µg/ml and 12.5µg/ml MIC values, respectively, compounds 5b and 5h demonstrated the most promising potency against E. coli, outperforming ampicillin, chloramphenicol, and ciprofloxacin. None of the substances had the same level of action as norfloxacin. 5a, 5d, 5g, 5h, and 5i have exhibited superior antifungal efficacy than Griseofulvin against C. albicans with 250µg/ml MIC. All the compounds were also individually docked into the E. coli DNA gyrase ATP binding site (PDB ID: 1KZN) and CYP51 inhibitor (PDB ID: 5V5Z). The most active compound, 5h and 5g displayed a Glide docking score of - 5.97kcal/mol and - 10.99kcal/mol against DNA gyrase and 14α-demethylase enzyme CYP51 respectively. Potent compounds 5b, 5h, and 5g may be used to design new, innovative antimicrobial agents, according to in vitro, ADMET, and in silico biological efficacy analyses.

One-pot synthesis of novel poly-substituted 3-cyanopyridines: Molecular docking, antimicrobial, cytotoxicity, and DFT/TD-DFT studies

Novel pyridine-3-carbonitrile derivatives, denoted as (4a-j), were synthesized using a convergent synthetic approach that involved a one-pot four-component reaction. This was achieved by utilizing a combination of various aromatic aldehydes, acetophenone derivatives, malononitrile, and four different sodium alkoxide solutions. The synthesized compounds were characterized using various spectroscopic techniques such as IR, 1HNMR , 13CNMR , and elemental analysis. Molecular docking simulations were employed to investigate the binding affinity of compounds (4a-j) towards two proteins, DHFR and HT-hTS. The results revealed that 4-(4-chlorophenyl)-2-ethoxy-6-phenyl-pyridine-3-carbonitrile (4a) compound exhibited the highest binding affinity score (ΔG = -8.06 Kcal/mol) upon docking into the active site of DHFR, while 2-(4-nitrophenyl)-6-(4-chlorophenyl)-4-ethoxy-pyridine-3-carbonitrile (4d) compound displayed the strongest binding affinity score (ΔG = -4.17 Kcal/mol) when docked to the active site of HT-hTS. These results were supported by the cytotoxic activity of selected compounds (4a, 4b, 4e, and 4 h) against human cancer cell lines (MCF7, HT29, and A2780) as well as normal human fetal lung fibroblast (MRC5) using MTT assay. The cytotoxicity analyses revealed that compound (4a) displayed cytotoxic activity against all cancer cell lines, particularly human colorectal carcinoma (HT29) with an IC50 value of 2.243±0.217 μM, which is lower than that of the reference drug (Doxorubicin) with an IC50 value of 3.964±0.360 μM. Furthermore, compound (4a) exhibited a lower cytotoxic effect on normal human fetal lung fibroblast (MRC5) with an IC50 value of 2.222±0.137 μM, as compared to the IC50 value of the reference drug (Doxorubicin) which was 2.476±0.033 μM. The antimicrobial activity of selected compounds such as (4a, 4c, and 4f) was also evaluated against a panel of microorganisms, including two gram-positive strains (Staphylococcus aureus and Enterococcus faecalis) and two gram-negative strains (Escherichia coli and Pseudomonas aeruginosa). The zone of inhibition and minimum inhibition concentration (MIC) demonstrated the potency of these compounds. Specifically, compounds 4-(4-chlorophenyl)-2-ethoxy-6-phenyl-pyridine-3-carbonitrile (4a) and 4-(4-methoxyphenyl)-2‑methoxy-6-(4-nitrophenyl)-pyridine-3-carbonitrile (4f) exhibited MIC of 0.013 µM against E. coli strains, which is comparable to that of the reference drug amoxicillin (MIC=0.01 µM). Finally, Density Functional Theory (DFT) and Time-Dependent Density Functional Theory (TDDFT) studies were performed on compounds (4a-j) to obtain a more comprehensive understanding of the structure-activity relationship and solvatochromic behavior of these molecules. Overall, the results suggest that compound (4a) could potentially serve as a promising cytotoxic and antibacterial agent with a better safety profile and reduced side effects on normal cells.

Synthesis of 1-Halophenyl-pyrazolophthalazine derivatives and evaluation of their antimicrobial activity.

Multi-component reactions for the preparation of pyrazolophthalazine derivatives under microwave irradiation from different aromatic aldehydes with a mixture malononitrile and phthalhydrazide derivatives were established. The antimicrobial activity of the target compounds was evaluated against four bacteria and two fungi using standard antibiotics Ampicillin and mycostatine as reference drugs. The structure-activity relationship studies reported that the substitution at 2,4, and 2,5-positions in the 1H-pyrazolo nucleus with the specific halogen atom increases the ability of the molecule against the antimicrobial activity. The structures of the synthesized compounds were established based on spectral data, IR, 1H NMR, 13C NMR and MS data. Design a series of new pyrazolophthalazine moieties and study the antimicrobial activity of these compounds Materials and Methods: pyrazolophthalazine derivatives 4a-j were synthesized by reaction of phthalhydrazide (1) with malononitrile (2), and various halogen aromatic aldehydes 3a-j in and EtOH/ Pip. Solution under microwave irradiation settings for two minutes at 140 °C Results: In this study, the antimicrobial activity of the synthesized compounds 4a-j was examined for their in vitro antimicrobial activity by using the agar diffusion method using Mueller-Hinton agar medium for bacteria and Sabouraud's agar medium for fungi. Ampicillin and mycostatine were included in the experiments as reference drugs. A series of new pyrazolophthalazine derivatives were synthesized in this work. All compounds were evaluated for antimicrobial activity.

Novel amide functionalized pyridine derivatives and their anticancer activity and molecular docking studies

A series of novel amide functionalized trifluoromethyl substituted pyridine derivatives were prepared starting from pyridine 1 on reaction with bromoethylacetate followed by reaction with different primary aliphatic amines, cyclic secondary amines or L-amino acids under different set of conditions. All the synthesized compounds 4a-j and 5a-d were screened for anticancer activity against four cancer cell lines such as HeLa-Cervical cancer (CCL-2), COLO 205-Colon cancer (CCL-222) HepG2- Liver cancer (HB-8065), MCF7-Breast cancer (HTB-22). 4j and 5d showed good activity.

Green synthesis, antimycobacterial evaluation and molecular docking studies of novel 2,3-dihydro-1H-pyrazol-4-ylnaphthalene-1,4-diones

A novel series of 2,3-dihydro-1H-pyrazol-4-ylnaphthalene-1,4-diones is synthesized via one-pot, multi-component condensation of ethyl acetoacetate, 4-(trifluoromethyl)phenylhydrazine, aromatic aldehydes and 7-fluoro-2-hydroxynaphthalene-1,4‑dione in aqueous p-toluenesulfonic acid (15 mol%) at 100 °C. The synthesized compounds (5a-j) were evaluated for their in vitro antimycobacterial efficacy against drug-sensitive and isoniazid-resistant Mycobacterium tuberculosis (Mtb) H37Rv strains using the broth based method. All compounds displayed good to better antimycobacterial activity with MIC values ranging from 0.49 to 5.16 µM. Compound 5i (MIC = 0.49±0.08 μM) demonstrated equivalent antimycobacterial activity as that of the reference drug isoniazid (MIC = 0.35±0.06 μM). Molecular docking of the synthesized compounds 5a-j with an active site of membrane transporter MmpL3 protein (PDB ID: 6AJJ) was performed to justify the results of in vitro antimycobacterial activity and offer insight into the possible mode of action and binding interaction of compounds with the receptor protein. Molecular descriptors and drug-like features of novel 2,3-dihydro-1H-pyrazol-4-ylnaphthalene-1,4-diones were also examined.

Design, synthesis, molecular docking and pharmacological evaluation of novel triazine-based triazole derivatives as potential anticonvulsant agents

Triazine-linked triazole compounds (4a-j) were designed, synthesized, and then examined for their anticonvulsant abilities. Compounds 4e, 4f, 4g, 4i, and 4j displayed significant anticonvulsant activity in both maximum electroshock seizure (MES) and pentylenetetrazole (PTZ) induced seizure during the preliminary screening. The phase II anticonvulsant activity statistics revealed that compounds 4e, 4f, 4g, 4i, and 4j demonstrated excellent activity as compared to the conventional drugs methaqualone and valproate, supporting the potential of these triazine-linked triazole analogues as novel anticonvulsant agents. To take use of the findings, computational parameters including docking analysis and drug-likeness prediction were carried out. Molecular modelling studies supported the essential pharmacophoric information that the structure activity relationship offered. The triazine-linked triazole analogues that were investigated might be viewed as helpful models for future research and derivatization.

New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization

A series of novel 1,2,3-triazole-linked ciprofloxacin-chalcones 4a-j were synthesised as potential anticancer agents. Hybrids 4a-j exhibited remarkable anti-proliferative activity against colon cancer cells. Compounds 4a-j displayed IC50s ranged from 2.53-8.67 µM, 8.67–62.47 µM, and 4.19–24.37 µM for HCT116, HT29, and Caco-2 cells; respectively, whereas the doxorubicin, showed IC50 values of 1.22, 0.88, and 4.15 µM. Compounds 4a, 4b, 4e, 4i, and 4j were the most potent against HCT116 with IC50 values of 3.57, 4.81, 4.32, 4.87, and 2.53 µM, respectively, compared to doxorubicin (IC50 = 1.22 µM). Also, hybrids 4a, 4b, 4e, 4i, and 4j exhibited remarkable inhibitory activities against topoisomerase I, II, and tubulin polymerisation. They increased the protein expression level of γH2AX, indicating DNA damage, and arrested HCT116 in G2/M phase, possibly through the ATR/CHK1/Cdc25C pathway. Thus, the novel ciprofloxacin hybrids could be exploited as potential leads for further investigation as novel anticancer medicines to fight colorectal carcinoma.

Synthesis and characterisation of formohydrazide derivatives as potential antimicrobial agents: molecular docking and DFT studies

A novel series of formohydrazide derivatives (3a-3j) were synthesised and characterised by FT-IR, 1H and 13C NMR spectral techniques. The geometrical parameters of compound 3d were calculated by using the DFT method B3LYP/6-311++G(d,p) basis set. The title molecule's dipole moment, polarizability, and first-order hyperpolarizability were calculated and interpreted. The HOMO–LUMO transition occurs when a molecule undergoes intra-molecular charge transfer. The reactive sites of the molecule are studied using the Molecular Electrostatic Potential (MEP) surface. In addition, using the DFT/B3LYP/6-311++G(d,p) level of theory, the Mulliken atomic charges of carbon, nitrogen, oxygen, chlorine, and hydrogen atoms were determined. The compounds 3a-j were tested for their in vitro antibacterial activity against five bacterial strains viz., Gram-Positive bacteria species Enterococcus faecalis, Staphylococcus aurous and Gram-Negative bacteria species Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa. The tested antimicrobial activities of the compounds were compared with the standard drug of Ciprofloxacin for bacteria and Ketocanazone for fungal. The compounds 3c, 3d and 3e showed excellent antifungal activities than the standard fungal strains. Molecular docking analysis was used to investigate the interaction of the title compound with a target protein.

Synthesis, characterization and antimicrobial activity of some new isoxazole derivatives

A series of isoxazole derivatives, 3-aryl-5-[5-(4-nitrophenyl)-2-furyl]-2,3-dihydroisoxazoles (5a-j) were synthesized by cyclocondensation reaction between 1-aryl-3-[5-(4-nitrophenyl)-2-furyl]prop-2-en-1-ones (4a-j) and hydroxylamine hydrochloride in presence of sodium acetate in glacial acetic acid at reflux temperature. Formerly, compounds (4a-j) were synthesized by the condensation of 5-(4-nitrophenyl) furan-2-carbaldehyde (3) with various aromatic ketones by using alkali as catalyst. The structures of the synthesized various isoxazole have been characterized by using elemental analysis, Infrared,1H-NMR spectroscopy and further supported by Mass spectroscopy. All the products have been screened for their in-vitro biological assay like antibacterial activity towards Gram-positive and Gram-negative bacterial strains and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. It was exposed that the compounds 5a, 5c, 5e, 5f, and 5i showed inspiring antibacterial and antifungal activity compared to the used reference standard.

Synthesis, characterization and biological study of some new N-acetyl pyrazole derivatives

A series of N-acetyl pyrazole derivatives, 1-acetyl-3-aryl-5-[5'-(4-nitrophenyl)-2'-furyl]-4,5-dihydro-1H-pyrazoles (5a-j) were synthesized by cyclocondensation reaction between 1-aryl-3-[5-(4-nitrophenyl)-2-furyl]prop-2-en-1-ones (4a-j) and hydrazine hydrate in glacial acetic acid at reflux temperature. Before that, compounds (4a-j) were synthesized by the condensation of 5-(4-nitrophenyl) furan-2-carbaldehyde (3) with various aromatic ketones by using alkali as catalyst. The constitution of the synthesized products has been characterized by using elemental analysis, Infrared,1H-NMR, 13C-NMR spectroscopy and further supported by Mass spectroscopy. All the products have been screened for their in-vitro biological assay like antibacterial activity towards Gram-positive and Gram-negative bacterial strains and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. It was exposed that the compounds 5a, 5b, 5c, 5d, 5g, 5h and 5j showed motivating antibacterial and antifungal activity compared to the used reference standard.

Synthesis of 2-aryl-5-(arylsulfonyl)-1,3,4-oxadiazoles as potent antibacterial and antioxidant agents.

Ten novel 2-aryl-5-(arylsulfonyl)-1,3,4-oxadiazoles were produced and assessed for their in vitro antibacterial and antioxidant activities. Diverse spectroscopic methods like 1H NMR, 13C NMR, IR, and LCMS were used for the characterization of the prepared samples and all the data was in good agreement with the anticipated structures. The prepared compounds 6a-j were screened for their in vitro antibacterial activity against bacterial strains Pseudomonas aeruginosa, Enterobacter aerogenes, Escherichia coli (gram-positive), and Bacillus cerus, Staphylococcus aureus, Bacillus subtilis (gram-negative). The antimicrobial screening outcome revealed that the prepared 2-(3,4-dimethylphenyl)-5-tosyl-1,3,4-oxadiazole (6j), 2-(3-isopropylphenyl)-5-tosyl-1,3,4-oxadiazole (6c), and 2-(2-ethylphenyl)-5-tosyl-1,3,4-oxadiazole (6i) are most potent among all the examined compounds. Furthermore, the antioxidant activity of the prepared compounds was also investigated by DPPH radical scavenging method and the results showed that some of the compounds were moderately active.